D-Y. Oh

1.2k citations
61 papers · 787 · h-index 14

Impact in

  • Oncology top 10%
    • Cancer Immunotherapy and Biomarkers
    • Colorectal Cancer Treatments and Studies
    • HER2/EGFR in Cancer Research
  • Gastroenterology top 5%
    • Gastrointestinal Tumor Research and Treatment

Papers in

  • Oncology 45
    • Colorectal Cancer Treatments and Studies 12
    • HER2/EGFR in Cancer Research 9
    • Pancreatic and Hepatic Oncology Research 8
    • Cancer Immunotherapy and Biomarkers 7
  • Pulmonary and Respiratory Medicine 31
    • Gastric Cancer Management and Outcomes 22
Co-authors
S-A Im (3 shared papers)Y-J. Bang (4 shared papers)W H Kim (1 shared paper)Hong Song (1 shared paper)S.R. Park (1 shared paper)Mina Kim (1 shared paper)Kyung-Woo Lee (7 shared papers)Takeshi Omori (3 shared papers)
Journals
Annals of Oncology (50 papers)British Journal of Cancer (4 papers)ESMO Open (2 papers)Journal of Molecular Endocrinology (1 paper)Cancer Research (1 paper)
Partner nations
South KoreaUnited StatesSpain

In The Last Decade

D-Y. Oh

55 papers receiving 777 citations

Peers

D-Y. Oh
Comparison fields: 5 of 53
  • Oncology 391
  • Gastroenterology 77
  • Pulmonary and Respiratory Medicine 288
  • Immunology 94
  • Surgery 181
Replace A. Polyzos with:
A. Polyzos Greece
Tom van den Ende Netherlands
Kara L. Hamilton‐Nelson United States
Gail D. Wenger United States
Daniel O. Kechele United States
Neil McCarthy United States
Terence Tan Singapore
Maria Teresa Radice Italy
Robert F. Willenbucher United States
D-Y. Oh relative to A. Polyzos Greece A. Polyzos's profile →
Citations per field
00.5×2×4×5.1×
A. Polyzos · 1×
Citations per year

Countries citing papers authored by D-Y. Oh

Since Specialization
Citations

This map shows the geographic impact of D-Y. Oh's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by D-Y. Oh with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites D-Y. Oh more than expected).

Fields of papers citing papers by D-Y. Oh

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by D-Y. Oh. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by D-Y. Oh. The network helps show where D-Y. Oh may publish in the future.

Co-authors

The 25 scholars most cited alongside D-Y. Oh, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with D-Y. Oh Line = papers co-authored together D-Y. Oh links everyone, so they are left out of the graph.

All Works

20 of 20 papers shown

Showing the 20 most-cited of 61 papers — load more, or switch the sort, to bring in the rest.

#Work
1
Phase II study and biomarker analysis of cetuximab combined with modified FOLFOX6 in advanced gastric cancer
British Journal of Cancer ·(unknown), D-Y. Oh, S-A Im, S.R. Park, (unknown), Hong Song, N.S. Lee, K. H. Lee, Ik Soo Choi, M. H. Lee, Mina Kim, W H Kim, Y-J. Bang, (unknown)
2009124
2
High tumour islet macrophage infiltration correlates with improved patient survival but not with EGFR mutations, gene copy number or protein expression in resected non-small cell lung cancer
British Journal of Cancer ·(unknown), Hanbo Min, (unknown), Yoon Jun Kim, D-Y. Oh, Yoon Kyung Jeon, (unknown), S-A Im, Doo Hyun Chung, Y T Kim, (unknown), Y-J. Bang, Sook Whan Sung, Jee Hyun Kim, Dae Seog Heo
200885
3
LBA7_PR Nivolumab plus chemotherapy versus chemotherapy alone in patients with previously untreated advanced or recurrent gastric/gastroesophageal junction (G/GEJ) cancer: ATTRACTION-4 (ONO-4538-37) study
Annals of Oncology ·Narikazu Boku, M.-H. Ryu, D-Y. Oh, Sang Cheul Oh, Hyun Cheol Chung, Kyung-Woo Lee, Takeshi Omori, Kohei Shitara, S. Sakuramoto, Ick‐Joong Chung, Kensei Yamaguchi, Katsuhiko Kato, Sun Jin Sym, Shigenori Kadowaki, Kunihiro Tsuji, Jin‐Shing Chen, L-Y. Bai, L-T. Chen, Y-K. Kang
202081
4
Molecular cloning, pharmacological characterization, and histochemical distribution of frog vasotocin and mesotocin receptors
Journal of Molecular Endocrinology ·Sujata Acharjee, J.-C. Do-Rego, D-Y. Oh, JS Moon, Ryun S. Ahn, K. Lee, DG Bai, Hubert Vaudry, HB Kwon, J Y Seong
200454
5
LBA73 Pathological complete response (pCR) to durvalumab plus 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT) in resectable gastric and gastroesophageal junction cancer (GC/GEJC): Interim results of the global, phase III MATTERHORN study
Annals of Oncology ·Yelena Y. Janjigian, S-E. Al-Batran, Zev A. Wainberg, Eric Van Cutsem, Daniela Molena, Kei Muro, Woo Jin Hyung, Lucjan Wyrwicz, D-Y. Oh, Takeshi Omori, Markus Moehler, Marcelo Garrido, Sofia Oliveira, Moïshe Liberman, Victor Castro Oliden, Mehmet Bilici, John F. Kurland, Ioannis Xynos, Helen Mann, Josep Tabernero
202348
6
The beneficial effect of palliative resection in metastatic colorectal cancer
British Journal of Cancer ·Jung‐Hyun Park, (unknown), (unknown), S-W Han, D-Y. Oh, S-A Im, Gyeong Hoon Kang, Eui Kyu Chie, S W Ha, S-Y Jeong, K J Park, (unknown), (unknown)
201341
7
Prognostic implication of mucinous histology in colorectal cancer patients treated with adjuvant FOLFOX chemotherapy
British Journal of Cancer ·Lee Dw, (unknown), H-J. Lee, Rhee Yy, Bae Jm, N-Y Cho, (unknown), Kim Ty, D-Y. Oh, Im Sa, Bang Yj, S-Y. Jeong, Ki‐Jong Park, (unknown), Gyeong Hoon Kang, (unknown)
201339
8
VP1-2023: Pembrolizumab (pembro) plus chemotherapy (chemo) as first-line therapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Phase III KEYNOTE-859 study
Annals of Oncology ·Sun Young Rha, L.S. Wyrwicz, P.E. Yanez Weber, Yibing Bai, M.H. Ryu, J. Lee, F. Rivera, G.V. Alves, Marcelo Garrido, K-K. Shiu, M. González Fernández, J. Li, M. Lowery, T. Çil, F.J.S.M. Cruz, S. Qin, L. Yin, S. Bordia, P. Bhagia, D-Y. Oh
202336
9
1916P Larotrectinib treatment of advanced TRK fusion thyroid cancer
Annals of Oncology ·Maria E. Cabanillas, Alexander Drilon, Anna F. Farago, Marcia S. Brose, Ray McDermott, Davendra Sohal, D-Y. Oh, M. Almubarak, Jessica R. Bauman, Edward Chu, Shivaani Kummar, Serge Leyvraz, K. Park, John A. Reeves, L. Dima, Patricia Maeda, Leonardo O. Rodrigues, Nicoletta Brega, David S. Hong, Steven G. Waguespack
202028
10
LBA12 Efficacy of RLY-4008, a highly selective FGFR2 inhibitor in patients (pts) with an FGFR2-fusion or rearrangement (f/r), FGFR inhibitor (FGFRi)-naïve cholangiocarcinoma (CCA): ReFocus trial
Annals of Oncology ·A. Hollebecque, Mitesh J. Borad, Lipika Goyal, A. Schram, J.O. Park, P.A. Cassier, Suneel D. Kamath, D.T. Wai Meng, E. Dotan, R. Kim, V. Sahai, D-Y. Oh, C-Y. Liao, M. Millward, D. Roda Perez, C. Ferté, R. Blakesley, B. Wolf, V. Subbiah, R.K. Kelley
202223
11
209P Interim results of a phase I/Ib study of SBT6050 monotherapy and pembrolizumab combination in patients with advanced HER2-expressing or amplified solid tumors
Annals of Oncology ·Samuel J. Klempner, M. Beeram, Dhanusha Sabanathan, Anthony W.H. Chan, Erika Hamilton, Sherene Loi, D-Y. Oh, Leisha A. Emens, Amita Patnaik, J.E. Kim, Y.H. Park, Valerie Odegard, Sue Hamke, Geundoo Jang, Céline Jacquemont, Naomi Hunder, Sarina A. Piha‐Paul
202122
12
654O Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with solid tumors harboring specific HER2-activating mutations (HER2m): Primary results from the international phase II DESTINY-PanTumor01 (DPT-01) study
Annals of Oncology ·Bob T. Li, Funda Meric‐Bernstam, Aditya Bardia, Yoichi Naito, Salvatore Siena, Philippe Aftimos, Ian C. Anderson, Giuseppe Curigliano, (unknown), Mamta Kalra, D-Y. Oh, J.O. Park, Sophie Postel‐Vinay, Sun Young Rha, Taroh Satoh, Iben Spanggaard, Flavia Michelini, Aaron Smith, K. K. Machado, C. Saura Manich
202320
13
56P Updated overall survival (OS) from the phase III TOPAZ-1 study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+ GC) in patients (pts) with advanced biliary tract cancer (BTC)
Annals of Oncology ·D-Y. Oh, A.R. He, S. Qin, L-T. Chen, T. Okusaka, A. Vogel, J.W. Kim, T. Suksombooncharoen, M.A. Lee, M. Kitano, H.A. Burris, M. Bouattour, S. Tanasanvimon, R.E. Zaucha, A. Avallone, J.E. Cundom, N. Rokutanda, M. Watras, G. Cohen, J.W. Valle
202219
14
1401O Trastuzumab deruxtecan (T-DXd) monotherapy and combinations in patients (pts) with advanced/metastatic HER2-positive (HER2+) esophageal, gastric or gastroesophageal junction adenocarcinoma (GEJA): DESTINY-Gastric03 (DG-03)
Annals of Oncology ·Y. Y. Janjigian, Hanneke W.M. van Laarhoven, Sun Young Rha, V S Kozlov, D-Y. Oh, A. Gravina, L. Rapatoni, H. Shoji, R.D. Hofheinz, L-T. Chen, Hugo Ford, Maxime Chénard-Poirier, Saeed Raoufmoghaddam, C. Lloyd, Chi Zhang, C. Mateo, Jae Man Lee
202415
15
1379P Margetuximab (M) with retifanlimab (R) in HER2+, PD-L1+ 1st-line unresectable/metastatic gastroesophageal adenocarcinoma (GEA): MAHOGANY cohort A
Annals of Oncology ·Daniel V.T. Catenacci, H. Park, Byoung Yong Shim, S.T. Kim, D-Y. Oh, Alexander I. Spira, Susanna V. Ulahannan, Eric J. Avery, Patrick M. Boland, Joseph Chao, Hyun Cheol Chung, F. Gardner, S.J. Klempner, Kyung-Woo Lee, Sang Cheul Oh, Julio A. Peguero, Mohamad Bassam Sonbol, Jichao Sun, Minori Koshiji Rosales, Y-K. Kang
202113
16
68O Impact of mutation status on efficacy outcomes in TOPAZ-1: A phase III study of durvalumab (D) or placebo (PBO) plus gemcitabine and cisplatin (+GC) in advanced biliary tract cancer (BTC)
Annals of Oncology ·J.W. Valle, S. Qin, L. Antonuzzo, D. Tougeron, CK Lee, B.J. Tan, M. Ikeda, V. Guthrie, P. McCoon, Y.S. Lee, N. Rokutanda, M. Żotkiewicz, G. Cohen, D-Y. Oh
202212
17
1523P Phase II dose optimization results from MOUNTAINEER-02: A study of tucatinib, trastuzumab, ramucirumab, and paclitaxel for HER2+ gastroesophageal cancer (GEC)
Annals of Oncology ·Mustapha Tehfé, J. Lee, Sun Young Rha, Yoshiaki Nakamura, Josep Tabernero, Kohei Shitara, D-Y. Oh, Jennifer R. Eads, J. Marshall, Zev A. Wainberg, Kyung-Woo Lee, Y-K. Kang, C-Y. Liao, Sung Yong Oh, Kun‐Huei Yeh, Donald Richards, Michelle Ubowski, K. Zhao, S. Bhaumik, John H. Strickler
20239
18
397MO Tislelizumab (TIS) plus chemotherapy (CT) vs placebo (PBO) plus CT in HER2-negative advanced or metastatic gastric or gastro-esophageal junction adenocarcinoma (GC/GEJC): PD-L1 biomarker analysis from RATIONALE-305
Annals of Oncology ·Markus Moehler, D-Y. Oh, Kazuyoshi Kato, Josep Tabernero, Marcia Cruz‐Correa, Lucjan Wyrwicz, Roberto Pazo-Cid, A. Cubillo, Ludovic Evesque, Lorenzo Fornaro, E. Dotan, Carys Morgan, L. Li, Yaling Xu, Tao Sheng, Shu‐Hua Yang, Hong Hu, R-H. Xu
20248
19
606O Initial results from a first-in-human study of the B7-H4-directed antibody-drug conjugate (ADC) AZD8205 (puxitatug samrotecan) in patients with advanced/metastatic solid tumors
Annals of Oncology ·Funda Meric‐Bernstam, Yoichi Naito, Stéphanie Gaillard, T. Shimoi, Vincent Chung, Andrew A. Davis, Theresa A. Proia, Amal Ayyoub, Manjusha Kulkarni, Sameer Upadhyay, Neil R. Miller, Nadia Luheshi, Andreea Varga, D-Y. Oh, Linda Mileshkin
20248
20
1518P Zanidatamab (zani) plus chemotherapy (chemo) and tislelizumab (tis) as first-line (1l) therapy for patients (pts) with advanced HER2-positive (+) gastric/gastroesophageal junction adenocarcinoma (GC/GEJC): Updated results from a phase Ib/II study
Annals of Oncology ·Kyung-Woo Lee, L-Y. Bai, Minkyu Jung, Jieer Ying, Y-H Im, D-Y. Oh, Y. Choi, Sang Cheul Oh, Yee Chao, (unknown), Y. Bao, Y-K. Kang
20237

About D-Y. Oh

D-Y. Oh is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Radiology, Nuclear Medicine and Imaging and Cancer Research, having authored 61 papers that have together received 787 indexed citations. Recurring topics across this work include Gastric Cancer Management and Outcomes (22 papers), Cholangiocarcinoma and Gallbladder Cancer Studies (14 papers), Colorectal Cancer Treatments and Studies (12 papers), HER2/EGFR in Cancer Research (9 papers), Monoclonal and Polyclonal Antibodies Research (8 papers), Pancreatic and Hepatic Oncology Research (8 papers), Cancer Genomics and Diagnostics (7 papers) and Cancer Immunotherapy and Biomarkers (7 papers). The work is most often cited by research in Oncology (391 citations), Gastroenterology (77 citations), Pulmonary and Respiratory Medicine (288 citations), Immunology (94 citations) and Surgery (181 citations). D-Y. Oh has collaborated with scholars based in South Korea, United States and Spain. Frequent co-authors include S-A Im, Y-J. Bang, W H Kim, Hong Song, S.R. Park, Mina Kim, Kyung-Woo Lee, Takeshi Omori, Dae Seog Heo and Gyeong Hoon Kang. Their work appears in journals such as Annals of Oncology, British Journal of Cancer, ESMO Open, Journal of Molecular Endocrinology and Cancer Research.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by A. PolyzosBreakdown of academic impact, for papers by Tom van den EndeBreakdown of academic impact, for papers by Kara L. Hamilton‐NelsonBreakdown of academic impact, for papers by Gail D. WengerBreakdown of academic impact, for papers by Daniel O. KecheleBreakdown of academic impact, for papers by Neil McCarthyBreakdown of academic impact, for papers by Terence TanBreakdown of academic impact, for papers by Maria Teresa RadiceBreakdown of academic impact, for papers by Robert F. Willenbucher